ImmunityBio held a Type B end‑of‑phase meeting with the U.S. Food and Drug Administration on January 20, 2026 to discuss a supplemental biologics license application (sBLA) for ANKTIVA in BCG‑unresponsive papillary non‑muscle‑invasive bladder cancer (NMIBC). The FDA outlined a clear resubmission path that would allow the company to submit additional data without initiating a new clinical trial, a development that could accelerate approval for the papillary indication.
The company’s ANKTIVA product is already approved in the United States for carcinoma in situ (CIS) with or without papillary tumors. In 2025, ImmunityBio’s initial sBLA for the papillary‑only indication was refused, prompting the current meeting. The FDA’s willingness to consider the new data package signals a significant shift in the regulatory stance and removes a major hurdle that had stalled the label expansion.
Clinical data from the QUILT‑3.032 study underpin the FDA’s confidence. The study reported a 12‑month disease‑free survival rate of 58.2 % and a 36‑month disease‑specific survival rate of 96 %. Importantly, more than 80 % of patients avoided radical cystectomy over a three‑year follow‑up, demonstrating a strong bladder‑sparing benefit that addresses a critical unmet need in this patient population.
Expanding ANKTIVA’s label to include papillary NMIBC would broaden the drug’s addressable market and strengthen ImmunityBio’s commercial position in the bladder‑cancer segment. The company plans to submit the requested information within 30 days, positioning the product for a faster regulatory decision and potentially accelerating revenue growth from a larger patient cohort.
CEO Richard Adcock emphasized the collaborative nature of the FDA discussion, noting that the agency’s guidance “provides a clear path forward and underscores the value of the data we have generated.” Dr. Patrick Soon‑Shiong, founder and executive chairman, highlighted the survival outcomes, stating that the combination of ANKTIVA and BCG “offers a survival advantage that surpasses other investigational therapies in this setting.”
The FDA’s guidance removes the need for a new clinical trial, a cost‑saving and time‑saving advantage that could bring ANKTIVA to patients sooner. By securing a broader label, ImmunityBio positions itself as a leading bladder‑sparing therapy, potentially capturing a larger share of the NMIBC market and reinforcing its pipeline momentum.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.